Cytek Biosciences
CTKB
165 hedge funds and large institutions have $372M invested in Cytek Biosciences in 2026 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 68 increasing their positions, 51 reducing their positions, and 11 closing their positions.
196% more call options, than puts
Call options by funds: $71K | Put options by funds: $24K
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
33% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 51
6% more funds holding
Funds holding: 155 → 165 (+10)
2.37% more ownership
Funds ownership: 64.15% → 66.53% (+2.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less capital invested
Capital invested by funds: $414M → $372M (-$42.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.27M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$3.75M |
| 3 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
+$3.45M |
| 4 |
SC
Simcoe Capital
Spokane,
Washington
|
+$2.76M |
| 5 |
Goldman Sachs
New York
|
+$2.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.86M |
| 2 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$2.8M |
| 3 |
TCM
Topline Capital Management
Santa Monica,
California
|
-$1.78M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.3M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.29M |
CTKB Hedge Fund Activity: Q1 2026 in Review
165 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q1 2026, worth a combined $372M — down 10% from $414M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CTKB positions and 11 closed out — a net gain of 13 holders — while 68 added to existing stakes and 51 trimmed.
The largest buyer was Millennium Management, adding an estimated $7.27M. The largest seller was Wellington Management Group, exiting entirely with an estimated $3.86M sold.
- 165 institutional investors held Cytek Biosciences (CTKB) as of Q1 2026, up from 155 in Q4 2025.
- Funds reported $372M of Cytek Biosciences stock for Q1 2026, down 10% quarter-over-quarter.
- 24 funds opened new Cytek Biosciences positions in Q1 2026 and 11 closed out, a net change of +13 holders.
- The largest Cytek Biosciences buyer in Q1 2026 was Millennium Management, an estimated $7.27M added.
- The largest Cytek Biosciences seller in Q1 2026 was Wellington Management Group, an estimated $3.86M sold.
Based on aggregated 13F filings for Q1 2026.